Insight

Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib

Photo taken from Antonio Passaro/X

Sep 2, 2024, 09:38

Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib

Antonio Passaro, shared a post on X:

“EMA approves amivantamab in combination with chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after Osimertinib (Mariposa2 combo).”

Read further.
Source: Antonio Passaro/X

Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Passaro leads lung cancer trials, evaluates therapeutic efficacy and safety. Authoring over 100 peer-reviewed papers, he also holds editorial positions and key roles in societies like ESMO and AIOM.

advanced lung cancer Amivantamab cancer Cancer research cancer treatment chemotherapy Drug Approval EGFR-mutated EMA approval Mariposa2 combo NSCLC OncoDaily Oncology Oncology News osimertinib

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage